Stimulation of neutralizing antibodies to human immunodeficiency virus type 1 in three strains of mice immunized with a 22 amino acid peptide of gp41 expressed on the surface of a plant virus

Vaccine

Volumn 14, Issue 8, 1996, Pages 799-810

  McLain, Lesley ^a   Durrani, Zarmina ^a   Wisniewski, Lisa Ann ^b   Porta, Claudine ^c   Lomonossoff, George P ^c   Dimmock, Nigel J ^a  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b Axis Genetics plc   (United Kingdom)

^c JOHN INNES CENTRE   (United Kingdom)

Author keywords

Cowpea mosaic virus; HIV 1; HIV 1 gp41; HIV 1 gp41 ELISA antibody; HIV 1 gp41 peptide; HIV 1 neutralizing antibody; Mouse immunization; Neutralizing antibody; Plant virus HIV chimera; Vaccine

Indexed keywords

GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; MOUSE; NONHUMAN; PLANT VIRUS; PRIORITY JOURNAL;

EID: 0030175998     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(95)00229-T     Document Type: Article

References (57)

1. 1 McKeating, J.A. Neutralization of human immunodeficiency virus. Rev. Med. Virol. 1992, 2, 35
2. 2 Putney, S. How antibodies block HIV infection: paths to an AIDS vaccine. TIBS 1992, 17, 191
3. 3 Wahren, B. New observations on functional and neutralizing humoral immune response to HIV. AIDS 1994, 8, S147
4. 4 Dimmock, N.J. Neutralization of animal viruses. Curr. Topics Microbiol. Immunol. 1993, 183, 1
5. 5 Dimmock, N.J. Update on the neutralization of animal viruses. Rev. Med. Virol. 1995, 5, 165
6. 6 Berman, P.W., Gregory, T.J., Riddle, L. et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature (Lond.) 1990, 345, 622
7. 7 Emini, E., Nara, P.L. and Schleif, W.A. Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees. J. Virol. 1990, 64, 3674
8. 8 Emini, E.A., Scheif, W.A., Nunberg, J.H. et al. Prevention of HIV infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature (Lond.) 1992, 355, 728
9. 9 Girard, M., Kaczorek, M., Pinter, A. et al. Immune response of chimpanzees to active immunization against HIV-1. J. Cell. Biochem. 1990, 14, 150
10. 10 Girard, M., Kieny, M.-P., Pinter, A. et al. Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus. Proc. Natl Acad. Sci. USA 1991, 88, 542
11. 11 Fultz, P.N., Nara, P., Barre-Sinousi, F. et al. Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells. Science 1992, 256, 1687
12. 12 Goedert, J., Drummond, J., Minkoff, H.L. et al. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity of low anti-gp120. Lancet 1989, 2, 1351
13. 13 Rossi, P., Moschese, V., Broliden, P.A. et al. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 correlates with the uninfected status of children born to seropositive mothers. Proc. Natl Acad. Sci. USA 1989, 86, 8055
14. 14 Devash, Y., Calvelli, T.A., Wood, D.G., Reagan, K.J. and Rubinstein, A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high affinity/ avidity maternal antibodies to the gp120 principal neutralizing domain. Proc. Natl Acad. Sci. USA 1990, 87, 3445
15. 15 Karpas, A., Hewlett, I.K., Hill, F. et al. Polymerase chain reaction evidence for human immunodeficiency virus type 1 neutralization by passive immunization in patients with AIDS or AIDS-related complex. Proc. Natl Acad. Sci. USA 1990, 87, 7613
16. 16 Osther, K., Wiik, A., Black, F. et al. Passive HIV-1 treatment of patients with HIV-1 infection. A preliminary report of a phase I trial of hyper-immune immunoglobulin to HIV-1. AIDS 1992, 6, 1457
17. 17 Robert-Guroff, M., Roilides, E., Muldoon, R. et al. Human immunodeficiency virus type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value. J. Infect. Dis. 1993, 167, 538
18. 18 Safrit, J.T., Fung, M.S.C., Andrews, C.A. et al. Hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 1993, 7, 15
19. 19 Parren, P.W.H.I., Ditzel, H.J., Gulizia, R.J. et al. Protection against human immunodeficiency virus type 1 in hu-PBL-SCID mice by passive immunization with a neutralizing monoclonal antibody against the gp120 CD4 binding site. AIDS 1995, 9, 1
20. 20 Hu, S.-L., Klaniecki, J., Dykers, T., Sridhar, P. and Travis, B.M. Neutralizing antibodies against HIV-1, BRU and SF2 isolates generated in mice immunized with recombinant vaccinia virus expressing HIV-1 (BRU) envelope glycoprotein and boosted with homologous gp160. AIDS Res. Human Retrovir. 1991, 7, 615
21. 21 Parry, C., McLain, L. and Dimmock, N.J. Production of long-lived neutralizing antibodies to HIV-1 IIIB in mice with a vaccinia recombinant virus-infected cell vaccine expressing gp160. AIDS Res. Human Retrovir. 1994, 10, 205
22. 22 Earl, P.L., Robert-Guroff, M., Matthews, T.J., Krohn, K., London, W.T. and Moss, B. Isolate-and group-specific immune responses to the envelope protein of human immunodeficiency virus induced by a live recombinant vaccinia virus in macaques. AIDS Res. Human Retrovir. 1989, 5, 23
23. 23 Zagury, D., Bernard, J., Cheynier, R. et al. A group-specific anamnestic reaction against HIV-1 induced by a candidate vaccine. Nature (Lond.) 1988, 332, 728
24. 24 Zagury, D., Léonard, R., Fouchard, M. et al. Immunization against AIDS in humans. Nature (Lond.) 1987, 326, 249
25. 25 Cooney, E.L., Collier, A.C., Greenberg, P.D. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337, 567
26. 26 Picard, O., Achour, A., Bernard, J. et al. A 2-year follow-up of an anti-HIV immune reaction in HIV-1 gp160-immunized healthy seronegative humans: evidence for persistent cell-mediated immunity. J. AIDS 1992, 5, 539
27. 27 Montefiori, D.C., Graham, B.S., Kliks, S. and Wright, P.F. Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160. J. Clin. Invest. 1992, 12, 429
28. 28 van Regenmortel, M.H.V. Structural and functional approaches to the study of protein antigenicity. Immunol. Today 1989, 10, 266
29. 29 Francis, M.J. and Clarke, B.E. Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell detirminants or hepatitis B core protein. Meth. Enzymol. 1989, 178, 659
30. 30 Adams, S.E., Dawson, K.M., Gull, K., Kingsman, S.M. and Kingsman, A.J. The expression of hybrid HIV-Ty virus-like particles in yeast. Nature (Lond.) 1987, 329, 68
31. 31 Clarke, B.E., Newton, S.E., Carrol, A.R. et al. Improved immunogenicity of a peptide epitope after fusion to hepatitis B core preotein. Nature (Lond.) 1987, 330, 381
32. 32 Stahl, S. and Murray, K. Immunogenicity of peptide fusions to hepatitis B core antigen. Proc. Natl Acad. Sci. USA 1989, 86, 6283
33. 33 Valenzuela, P., Coit, D., Medina-Selby, A. et al. Antigen engineeing in yeast: synthesis and assembly of hybrid hepatitis B surface antigen-herpes simplex gD particles. Bio/Technol. 1985, 3, 323
34. 34 Delpeyroux, F., Chenciner, N., Lim, A. et al. A poliovirus neutralization epitope expressed on hybrid hepatitis B surface antigen particles. Science 1986, 233, 472
35. 35 Michel, M.L., Mancini, M., Schlienger, K. and Tiollais, P. Recombinant hepatitis B surface antigen as a carrier of human immunodeficiency virus epitopes. Res. Virol. 1993, 144, 263
36. 36 Burke, K., Dunn, G., Ferguson, M., Minor, P.D. and Almond, J.F. Antigen chimeras of poliovirus as potential new vaccines. Nature (Lond.) 1988, 332, 81
37. 37 Evans, D.J., McKeating, J.A., Meredith, J.M. et al. An engineered poliovirus chimaera elicits broadly reactive HIV-1 neutralizing antibodies. Nature (Lond.) 1989, 339, 385
38. 38 Minor, P.D. Antigenic structure of picornaviruses. Curr. Topics Microbiol. Immunol. 1990, 161, 121
39. 39 Reimann, B.-Y., Zell, R. and Kandolf, R. Mapping of a neutralizing antigenic site of coxsackievirus B4 by construction of an antigenic chimera. J. Virol. 1991, 65, 3475
40. 40 Kitson, J.D.A., Burke, K.L., Pullen, L.A., Belsham, G.J. and Almond, J.W. Chimeric polioviruses that include sequences derived from two independent antigenic sites of foot-and-mouth disease virus (FMDV) induce neutralizing antibodies against FMDV in guinea pigs. J. Virol. 1991, 65, 3068
41. 41 Dedieu, J.-F., Ronco, J., van der Werf, S., Hogle, J.M., Henin, Y. and Girard, M. Poliovirus chimeras expressing sequences from the principal neutralization domain of human imunodeficiency virus type 1. J. Virol. 1992, 66, 3161
42. 42 Li, S., Schulman, J.L., Moran, T., Bona, C. and Palese, P. Influenza A virus transfectants with chimeric hemagglutinins containing epitopes from different subtypes. J. Virol. 1992, 66, 399
43. 43 Muster, T., Guinea, R., Trkola, A. et al. Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS. J. Virol. 1994, 68, 4031
44. 44 Murdin, A.D., Su, H., Llein, M.H. and Caldwell, H.D. Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV off the major outer membrane protein of Chlamydia trachomitis elicit broadly reactive C. trachomitis-neutralizing antibodies. Infect. Immun. 1995, 63, 1116
45. 45 McLain, L., Porta, C., Lomonossoff, G.P., Durrani, Z. and Dimmock, N.J. Human immunodeficiency virus type 1 neutralizing antibodies raised to a gp41 peptide expressed on the surface of a plant virus. AIDS Res. Human Retrovir. 1995, 11, 327
46. 46 Kennedy, R.C., Henkel, R.D., Pauletti, D. et al. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science 1986, 231, 1556
47. 47 Chanh, T.C., Dreesman, G., Kanda, P. et al. Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J. 1986, 5, 3065
48. 48 Dalgleish, A.G., Chanh, T.C., Kennedy, R.C., Kanda, P., Clapham, P.R. and Weiss, R.A. Neutralization of diverse strains of HIV-1 by monoclonal antibodies raised against a gp41 synthetic peptide. Virology 1988, 165, 209
49. 49 Vella, C., Ferguson, M., Dunn, G., Meloen, R., Langedijk, H., Evans, D. and Minor, P.D. Characterization and primary structure of a human immunodeficiency virus type 1 (HIV-1) neutralization domain as presented by a poliovirus type 1/HIV-1 chimera. J. Gen. Virol. 1993, 74, 2603
50. 50 Usha, R., Rohll, J., Spall, V.E. et al. Expression of an animal virus antigenic site on the surface of a plant virus particle. Virology 1993, 197, 366
51. 51 Porta, C., Spall, V.E., Loveland, J., Johnson, J.E., Barker, P.J. and Lomonossoff, G.P. Development of cowpea mosaic virus as a high yielding system for the presentation of foreign peptides. Virology 1994, 202, 949
52. 52 Dessens, J.T. and Lomonossoff, G.P. Mutational analysis of the putative catalytic triad of the cowpea mosaic virus 24K protease. Virology 1991, 184, 738
53. 53 van Kammen, A. and de Jager, C.P. Cowpea mosaic virus. In: CMI/AAB Descriptions of Plant Viruses, 1978, p. 197. Commonwealth Agricultural Bureaux
54. 54 McLain, L. and Dimmock, N.J. Single-and multi-hit kinetics of immunoglobulin G neutralization of human immunodeficiency virus type 1 by monoclonal antibodies. J. Gen. Virol. 1994, 75, 1457
55. 55 McLain, L., Durrani, Z., Wisniewski, L.A., Porta, C., Lomonossoff, G.P. and Dimmock, N.J. A plant virus-HIV-1 chimera stimulates antibody that neutralizes HIV-1. In: Vaccines 96 (Ed. Brown, F., Burton, D.R., Collier, J., Mekalanos, J. and Norrby, E.). Cold Spring Harbor Press, New York, 1996, in press
56. 56 Porta, C., Spall, V.E., Lin, T., Johnson, J.E. and Lomonossoff, G.P. The development of cowpea mosaic virus as a potential source of novel vaccines. Intervirology 1995, in press
57. 57 Brown, A.L., Francis, M.J., Hastings, G.Z. et al. Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. Vaccine 1991, 9, 595